Potential clinical application of anti-Müllerian hormone testing in radioiodine treatment of thyroid carcinoma
Language English Country Great Britain, England Media electronic
Document type Journal Article
Grant support
480122
Charles University, Faculty of Medicine in Hradec Králové
PubMed
38783369
PubMed Central
PMC11119708
DOI
10.1186/s13104-024-06802-y
PII: 10.1186/s13104-024-06802-y
Knihovny.cz E-resources
- Keywords
- Anti-Müllerian hormone, Ovarian reserve, Premature ovarian failure, Radioiodine treatment of thyroid cancer,
- MeSH
- Anti-Mullerian Hormone * blood MeSH
- Adult MeSH
- Humans MeSH
- Thyroid Neoplasms * radiotherapy blood MeSH
- Ovarian Reserve * drug effects MeSH
- Prospective Studies MeSH
- Iodine Radioisotopes * therapeutic use MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Anti-Mullerian Hormone * MeSH
- Iodine Radioisotopes * MeSH
Differentiated thyroid cancer is the most common endocrinological malignancy. Radioiodine treatment has a clear benefit in locally aggressive and metastatic cancers. There are discussions about long-term and acute adverse events.Anti-Müllerian hormone is regarded as the best endocrine marker for evaluating the physiological loss of oocytes in healthy women with regard to age. The impact of radioiodine treatment on anti-Müllerian hormone levels has been more significantly reported in patients over 35 years of age. About reproductive dysfunction, calculations of individual absorbed doses of radioiodine in ovaries after thyroid cancer therapy have not been performed yet. The aim of our ongoing prospective study is to determine serum anti-Müllerian hormone to estimate ovarian reserve for premenopausal women treated with radioiodine and to compare anti-Müllerian hormone levels before and after radioiodine treatment. Predicting radioiodine side effects by evaluating a simple serum biomarker may help to select an appropriate treatment strategy for young women planning pregnancy, specifically in the assessment of ovarian reserve and premature ovarian failure with early onset of menopause.
See more in PubMed
Wong QHY, Anderson RA. The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery. Curr Opin Endocrinol Diabetes Obes. 2018;25(6):391–8. doi: 10.1097/MED.0000000000000447. PubMed DOI PMC
Jankowska K. Premature ovarian failure. Menopause Review/Przegląd Menopauzalny. 2017;16(2):51–6. PubMed PMC
Kučera R, Topolčan O, Rumpíková T, Rumpík D, Dostál J. Stanovení anti-Müllerova hormonu u žen [Determination of anti-Müllerian hormone in women] Ceska Gynekol. 2013;78(3):282–8. PubMed
Lebl J, Taji EA, Koloušková S, Průhová Š, Šnajderová M, Šumník Z. Dětská endokrinologie a diabetologie. 1. Praha: Galén; 2016. pp. 315–9.
Rajpert-De Meyts E, Jørgensen N, Graem N, Müller J, Cate RL, Skakkebaek NE. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84(10):3836–44. PubMed
Victoria M, Labrosse J, Krief F, Cédrin-Durnerin I, Comtet M, Grynberg M. Anti Müllerian hormone: more than a biomarker of female reproductive function. J Gynecol Obstet Hum Reprod. 2019;48(1):19–24. doi: 10.1016/j.jogoh.2018.10.015. PubMed DOI
Marek J, Hána V, Endokrinologie. 1 ed., Praha: Galén 2017; 387–9.
Feyereisen E, Lozano DHM, Taieb J, Hesters L, Frydman R, Fanchin R. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006;12(6):695–703. doi: 10.1016/S1472-6483(10)61081-4. PubMed DOI
Vlček P, Nováková D, Katra R. Karcinomy štítné žlázy: současný pohled na diagnostiku a léčbu [Thyroid carcinomas: the present view on diagnostics and therapy] Vnitr Lek. 2017;63(9):572–9. doi: 10.36290/vnl.2017.115. PubMed DOI
Zec I, Tislaric-Medenjak D, Bukovec Megla Z, Kucak I. Anti-Müllerian hormone: a unique biochemical marker of gonadal development and fertility in humans. Biochemia Med. 2011;21(3):219–30. doi: 10.11613/BM.2011.031. PubMed DOI
Blahoš J, Zamrazil V. Endokrinologie - interdisciplinární obor. Praha: Triton; 2006.
Řežábek K. Asistovaná reprodukce. Praha: Maxdorf, 2014.
Moolhuijsen LME, Visser JA. Anti-Müllerian hormone and Ovarian Reserve: update on assessing ovarian function. J Clin Endocrinol Metabolism. 2020;105(11):3361–73. doi: 10.1210/clinem/dgaa513. PubMed DOI PMC
Dietlein M, Grünwald F, Schmidt M, Schneider P, Verburg FA, Luster M. Radioiodine therapy for benign thyroid diseases (version 5) German Guideline Nuklearmedizin. 2016;55(6):213–20. PubMed
Wu JX, Young S, Ro K, Li N, Leung AM, Chiu HK, Harari A, Yeh MW. Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer. Thyroid. 2015;25(1):133–8. doi: 10.1089/thy.2014.0343. PubMed DOI PMC
